INTRODUCTION
============

Kidney transplant (KT) is the best therapeutic alternative for most causes of chronic renal failure [@B1], [@B2], where avoiding the chronic renal allograft dysfunction (CRAD) is essential [@B3]. The CRAD is a multifactorial pathological entity characterized by a progressive decrease in glomerular filtration rate, generally associated with proteinuria and arterial hypertension [@B4]. Nowadays, KT outcomes are not completely understood, but there is growing evidence that mitochondrial genetic background may contribute to differences between individuals in this complex disease.

Mitochondria are the main energy-producing organelles in mammalian cells, but they also play a central role in cell injury and death signaling. In addition, mitochondria dysfunction plays a critical role in the pathogenesis of kidney diseases and it has been related to renal failure [@B5]. Mitochondrial DNA (mtDNA) is highly polymorphic due to the fact that specific mtDNA polymorphisms have been acquired throughout human history. Based on these polymorphisms, we are able to classify the human population into a number of discrete mitochondrial clades or haplogroups[@B6]. Variations in mtDNA have been directly associated with susceptibility to chronic diseases [@B7], and contribute to differences in mitochondrial function, such as reactive oxygen species (ROS) production and oxidative phosphorylation capacity [@B8], [@B9], affecting the function of the immune system [@B10]. In this setting, mtDNA haplogroup H has been previously related to transplant-related complications [@B11]. However, the influence of mtDNA haplogroups on the development of allograft failure has not been studied so far. Thus, the aim of this study was to analyze the association of mtDNA haplogroups with the development of CRAD in patients with KT.

PATIENTS AND METHODS
====================

A retrospective observational study was carried out on 261 patients who received KT in the "Hospital Clínico Universitario" in Valladolid (Spain), between 1995 and 2008. Patients were classified into two groups according to their kidney graft outcomes: a) Non-CRAD: patients with stable transplant or absence of CRAD; b) CRAD: patients who developed CRAD. CRAD was considered as any decrease ≥30% of the inverse of creatinine (1/Cr) after the third month of transplantation, using as baseline the highest value of 1/Cr in the first three months after transplantation, as previously described by Kasiske et al [@B12]. Demographic and clinical data were obtained from medical records. Patients who were younger than 18 years and/or had unavailable DNA sample were ruled out. Written consent was obtained from all patients and the Ethics Committee approved the study.

DNA samples were genotyped for 14 mtDNA polymorphisms that define European mtDNA haplogroups (adapted from Hendrickson et al [@B13]) at the Spanish National Genotyping Center (CeGen; <http://www.cegen.org/>) by using Sequenom\'s MassARRAY platform (San Diego, CA, USA) with the iPLEX® Gold assay design system. Our study included only European white participants within the N macro-cluster, which is ancestral to almost all the European and many of the Eurasian haplogroups [@B6]. These subjects (N macro-cluster) were further parsed into the most common European major-haplogroups or clusters (HV, U, JT and IWX,) and haplogroups (H, V, pre-V, J, T, I, W and X).

Chi-squared/Fisher tests and Mann-Whitney U tests were used for comparison of variables across groups. Logistic regression was used to assess the relationship between mtDNA haplogroups and development of CRAD. For multivariate analysis, age and gender of recipients and donors, HLA mismatches and cold ischemia time were used to select the most significant covariates by a stepwise algorithm (at each step, factors are considered for removal or entry: a p-value for entry of 0.20 and exit of 0.15). Statistical analysis was performed by SPSS 19.0 software (SPSS INC, Chicago, IL, USA). All tests were two-tailed with p-values \<0.05 considered significant.

RESULTS
=======

**Table [1](#T1){ref-type="table"}**shows the clinical characteristics of 261 patients included in our study: 114 were within Non-CRAD group, and 147 within CRAD group**.**

**Figure [1](#F1){ref-type="fig"}** shows the frequencies of mtDNA haplogroups according to CRAD. Patients with CRAD showed higher frequency of haplogroup H (p= 0.049) and a lower tendency of haplogroups V and J (p=0.071 and p=0.079, respectively). The cluster IWX and haplogroups I, X, and W had frequencies of less than 5%, and were discarded for the association analysis.

**Table [2](#T2){ref-type="table"}** shows the likelihood of developing CRAD according to mtDNA haplogroups. Patients with haplogroups V (odds ratio (OR)= 0.32; p= 0.037) and J (OR= 0.36; p= 0.038) had lower odds of developing CRAD than patients with haplogroup H. After adjusting for the most significant variables, haplogroups V and J tended to statistical significance (p=0.091 and p=0.067 respectively).

DISCUSSION
==========

To our knowledge, this is the first study that investigates the association between the European mtDNA and the development of CRAD in KT patients. In our study, haplogroup H showed a tendency to worsen the outcome of renal allograft, while haplogroups V and J showed a trend towards lower odds of CRAD, although statistical significance did not remain after multivariate analysis.

Regarding KT, haplogroup H has been related to complications in renal transplanted patients such as new-onset diabetes in a recent article [@B11], which could suggest that haplogroup H is a risk factor for a worse outcome. This risk could be explained by the differences in mitochondrial function among different mtDNA haplogroups. In this setting, mitochondrial haplogroup H has been demonstrated to have higher activity in the electron transport chain, producing higher quantities of ATP and ROS than other haplogroups, such as J, which exhibits lower energy efficiency [@B8], [@B9]. Besides, an increase of stress oxidative markers, as well as a decrease in antioxidant defense mechanisms in transplant recipients with chronic allograft failure, has been also described [@B14]. In this regard, the presence of haplogroup H (related to higher ROS production) could contribute to increased oxidative damage, leading to higher probability of renal failure; whereas haplogroup J (lower ROS production) could be related to decreased odds of developing CRAD.

Finally, it should be taken into account that our study is retrospective and has a limited sample size, which might be responsible for the lack of statistical association in the multivariate model. Therefore, this study could be considered as a preliminary study. The mtDNA haplogroups seem to be implicated in susceptibility or protection for developing CRAD. However, further studies with larger sample size and different populations would be interesting in order to corroborate the possible influence of mtDNA on outcome of renal allograft.
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###### 

Clinical characteristics of patients with renal allograft transplant.

  Characteristics                   Non-CRAD              CRAD               p-value
  --------------------------------- --------------------- ------------------ ---------
  **No.**                           114                   147                
  **Receptor**                                                               
  Age ^a^                           50 (42.7-57.2)        52 (42-60)         0.250
  Male ^b^                          51 (44.7)             49 (33.3)          0.060
  Primary disease ^b^                                                        
  Glomerulonephritis                32 (28.1)             43 (29.3)          0.780
  Arterial hypertension             14 (12.3)             14 (9.5)           0.499
  Diabetic nephropathy              8 (7)                 11 (7.5)           0.862
  Tubulointerstitial nephritis      9 (7.9)               18 (12.2)          0.237
  Obstructive uropathy              6 (5.3)               5 (3.4)            0.543
  Vascular causes                   4 (3.5)               0 (0)              0.036
  Polycystic kidney disease         18 (15.8)             17 (11.6)          0.342
  Others/Unknown                    23 (20.2)             39 (26.5)          
  **Donor**                                                                  
  Age ^a^                           46 (28.7-55)          53 (39-60)         0.002
  Male ^b^                          78 (68.4)             98 (66.7)          0.764
  Cause of death ^b^                                                         
  CVA                               55 (48.2)             85 (57.8)          0.124
  TBI                               11 (9.6)              13 (8.8)           0.823
  Others                            48 (42.1)             49 (33.3)          
  **Transplant factors**                                                     
  HLA A mismatches^b^                                                        0.510
  0                                 65 (57)               74 (50.7)          
  1                                 45 (39.5)             68 (46.6)          
  2                                 4 (3.5)               4 (2.7)            
  HLA B mismatches^b^                                                        0.969
  0                                 77 (67.5)             99 (67.8)          
  1                                 35 (30.7)             45 (30.8)          
  2                                 2 (1.8)               2 (1.4)            
  HLA DR mismatches^b^                                                       0.834
  0                                 13 (11.4)             16 (11)            
  1                                 91 (79.8)             120 (82.2)         
  2                                 10 (8.8)              10 (6.8)           
  Cold ischemia time (minutes)^a^   693.5 (600.0-913.7)   849.0 (600-1023)   0.023

CRAD: chronic renal allograft dysfunction; CVA: cerebrovascular accident; TBI: traumatic brain injury.

^a^ Median (interquartile rank). ^b^ Absolute number (percentage). NA: not applicable

###### 

Likelihood of developing chronic renal allograft rejection (CRAD) according to European haplogroups. (a) The most significant covariates were selected by a stepwise algorithm. Significant values are marked in bold.

                    Unadjusted          Adjusted ^(a)^                       
  ----------------- ------------------- ---------------- ------------------- -------
  **Clusters**                                                               
  HV                Reference           \-               Reference           \-
  U                 0.89 (0.49; 1.63)   0.708            0.95 (0.50; 1.78)   0.864
  JT                0.65 (0.32; 1.30)   0.221            0.65 (0.32; 1.32)   0.233
  **Haplogroups**                                                            
  H                 Reference                            Reference           \-
  V                 0.32 (0.11; 0.93)   **0.037**        0.38 (0.12; 1.17)   0.091
  Pre-V             0.89 (0.30; 2.66)   0.832            0.95 (0.30; 2.96)   0.926
  J                 0.36 (0.14; 0.95)   **0.038**        0.39 (0.14; 1.07)   0.067
  T                 0.89 (0.34; 2.34)   0.810            0.81 (0.29; 2.28)   0.690

Abbreviations: OR, odds ratio; 95%CI, 95% of confidence interval; p-value, statistical significance.
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